Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Last trade$117.04
Day change+$9.56 (+8.89%)
Day range$104.26 – $118.25
Volume1,898,165
Market cap$7.45B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.45B
Price / earnings
—
Price / book
36.97×
Price / sales
26.54×
EV / sales
26.77×
EV / EBITDA
-40.35×
Profitability
Earnings per share
-$2.86
Return on assets
-44.75%
Return on equity
-98.39%
Dividend yield
0.02%
Liquidity and leverage
Debt / equity
0.51×
Current ratio
2.78×
Quick ratio
2.57×
Cash ratio
0.26×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$83.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RYTM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$92.13M
$71.26M
$60.11M
$57.25M
$51.3M
$48.5M
$32.7M
$41.83M
Cost of revenue
$12.17M
$8.93M
$7.16M
$4.8M
$5.5M
$5.54M
$3.65M
$3.79M
Gross profit
$79.96M
$62.32M
$52.96M
$52.45M
$45.8M
$42.96M
$29.06M
$38.04M
Selling, general and administrative
$66.75M
$67.45M
$63.59M
$57.48M
$52.43M
$45.95M
$39.09M
$38.13M
Research and development
$52.48M
$43.43M
$41.73M
$42.03M
$46.03M
$42.31M
$36.97M
$41.17M
Total operating expenses
$119.23M
$110.88M
$105.32M
$99.51M
$98.45M
$88.26M
$76.06M
$79.3M
Operating income
-$39.27M
-$48.55M
-$52.36M
-$47.06M
-$52.65M
-$45.3M
-$47M
-$41.26M
Interest expense
-$4.5M
-$4.54M
-$4.58M
-$4.62M
-$4.74M
-$5.82M
-$5.41M
-$5.45M
Income before taxes
-$40.76M
-$48.85M
-$55.09M
-$47.54M
-$52.79M
-$46.3M
-$49.42M
-$43.38M
Income taxes
$610K
$444K
$545K
-$31K
$111K
$337K
$80K
-$90K
Net income
-$41.37M
-$49.3M
-$55.64M
-$47.51M
-$52.9M
-$46.63M
-$49.5M
-$43.29M
Net income attributable to common shareholders
-$42.35M
-$50.36M
-$56.74M
-$48.84M
-$54.28M
-$47.98M
-$50.82M
-$44.63M
EBITDA
-$39.02M
-$48.3M
-$52.11M
-$46.79M
-$52.35M
-$44.92M
-$46.62M
-$40.87M
Basic earnings per share
-$0.61
-$0.73
-$0.83
-$0.73
-$0.82
-$0.75
-$0.81
-$0.72
Diluted earnings per share
-$0.61
-$0.73
-$0.83
-$0.73
-$0.82
-$0.75
-$0.81
-$0.72
Recent news
Company coverage with links to the original publishers.
Rhythm Pharmaceuticals announced that the UK's National Institute for Health and Care Excellence (NICE) has expanded its positive guidance for IMCIVREE (setmelanotide) to include adults with genetically confirmed Bardet-Biedl syndrome, allowing NHS funding for this patient population. The expansion builds on previous 2024 guidance that covered patients ages 6-17 and recognizes the significant burden of hyperphagia and obesity associated with the disease throughout adulthood.
Rhythm Pharmaceuticals reported a Q3 loss of $0.61 per share, beating consensus estimates of $0.68 loss, with a 10.29% earnings surprise. Revenue reached $92.13 million, surpassing estimates by 9.07% and nearly doubling year-ago revenues of $51.3 million. However, the stock has underperformed the market, down 12.7% year-to-date versus the S&P 500's 10.2% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Rhythm Pharmaceuticals amended its global licensing agreement with LG Chem for bivamelagon, reducing royalties from low-to-mid-single digits to 1% on MC4R agonist sales while committing to $350 million in fixed payments over four years. The company also secured a $750 million term-loan facility led by KKR's HealthCare Royalty and Blackstone to support the agreement, commercialization efforts, and pipeline development.
Rhythm Pharmaceuticals (RYTM) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +1.38% and Zacks Rank #3. The company is projected to report a quarterly loss of $0.68 per share (improved from $0.81 year-ago) with revenues of $84.47 million, up 64.7% year-over-year. The stock has beaten consensus EPS estimates in 3 of the last 4 quarters.
Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan following MHLW approval and inclusion on Japan's National Health Insurance drug price list. IMCIVREE is the first approved therapy in Japan for acquired hypothalamic obesity, with an estimated patient population of 5,000-8,000 people. The approval was supported by Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.